Research programme: anti-inflammatory and immunological disorders therapeutics - Palleon Pharmaceuticals
Latest Information Update: 31 Mar 2025
At a glance
- Originator Palleon Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 26 Mar 2025 Early research in Immunological disorders in USA (unspecified route) prior to March 2025 (Palleon Pharmaceuticals pipeline, March 2025)
- 26 Mar 2025 Early research in Inflammation in USA (unspecified route) prior to March 2025 (Palleon Pharmaceuticals pipeline, March 2025)